OPKO Health, Inc. Debt Conversion, Converted Instrument, Amount
OPKO Health, Inc. (OPK) reported Debt Conversion, Converted Instrument, Amount of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-01.
Financial Statements › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2026-08-28
- OPKO Health, Inc. debt conversion, converted instrument, amount for the quarter ending 2022-12-31 was $0.00.
- OPKO Health, Inc. debt conversion, converted instrument, amount for the quarter ending 2022-09-30 was $0.00.
- OPKO Health, Inc. debt conversion, converted instrument, amount for the quarter ending 2021-12-31 was $0.00.
- OPKO Health, Inc. debt conversion, converted instrument, amount for the quarter ending 2021-09-30 was $0.00.
- OPKO Health, Inc. debt conversion, converted instrument, amount for fiscal 2023 was $0.00.
- OPKO Health, Inc. debt conversion, converted instrument, amount for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- OPKO Health, Inc. debt conversion, converted instrument, amount for fiscal 2021 was $68.78M.
- OPKO Health, Inc. debt conversion, converted instrument, amount for fiscal 2020 was $0.00.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month | Debt Conversion, Converted Instrument, Amount 48 month |
|---|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-01 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $0.00 derived: sum of 2 quarters · filed 2024-03-01 | $0.00 10-K · filed 2024-03-01 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $0.00 derived: sum of 2 quarters · filed 2024-03-01 | $68.78M 10-K · filed 2024-03-01 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $68.78M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $68.78M 10-Q · filed 2022-08-04 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $0.00 10-K · filed 2023-02-27 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $0.00 10-Q · filed 2021-10-28 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-07-29 | ||||
| 2016-12-31 | $143.20M 10-Q/A · filed 2026-08-28 | ||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $0.00 10-K · filed 2014-03-03 | |||
| 2012-09-30 | $0.00 10-Q · filed 2013-11-12 | ||||
| 2011-12-31 | $0.00 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |